How much life expectancy can Canagliflozin (SGLT2 inhibitor) add?

Based on population-weighted modelling, Canagliflozin (SGLT2 inhibitor) is associated with an estimated +1.0 years of life expectancy on average. Individual results depend on baseline health, adherence level, and age of intervention.

What is the evidence score for Canagliflozin (SGLT2 inhibitor)?

Canagliflozin (SGLT2 inhibitor) has an overall evidence score of 60/100 on Stacking Years, based on a weighted combination of 4 peer-reviewed studies (85% weight) and expert consensus (15% weight).

Which longevity experts recommend Canagliflozin (SGLT2 inhibitor)?

Canagliflozin (SGLT2 inhibitor) is endorsed or discussed by longevity experts including Brian Kennedy, PhD, Peter Attia, MD, Peter Diamandis, MD. See their full protocols and citations on Stacking Years.

Is Canagliflozin (SGLT2 inhibitor) safe?

Canagliflozin (SGLT2 inhibitor) is a pharmaceutical. Safety depends on individual health status, dosing, and interactions with medications. Always consult a qualified healthcare provider before starting any new health protocol.

Canagliflozin (SGLT2 inhibitor)

Estimated longevity benefit: +1.0 years. Evidence score: 60/100.

SGLT2 inhibitor that causes urinary glucose excretion and extended mouse lifespan by +14% in males in the NIA ITP — a sex-specific finding with a critical warning: the same drug may reduce lifespan in aged females at elevated blood concentrations.